Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Wiskott-Aldrich syndrome-like protein (WASL) mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the WASL transcript, which encodes the N-WASP protein (UniProt P46108). N-WASP is a key scaffold protein that activates the Arp2/3 complex, driving branched actin polymerization essential for cell motility, endocytosis, and the formation of invasive structures like invadopodia (NCBI Gene ID: 8976). The 3'UTR serves as a hub for post-transcriptional regulation, containing multiple binding sites for tumor-suppressive microRNAs, such as miR-145 and miR-218, which repress WASL expression (PubMed: 23103957, 25103498). In many aggressive cancers, the loss of these regulatory microRNAs leads to the pathological overexpression of WASL, significantly increasing the metastatic potential of tumor cells. Consequently, the WASL mRNA 3'UTR is an attractive target for RNA-based therapeutics, including microRNA mimics and antisense oligonucleotides, aimed at restoring translational repression and inhibiting cancer cell invasion.
MicroRNA-mediated gene silencing and translational repression
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Wiskott-Aldrich syndrome-like protein mRNA 3' untranslated region (WASL mRNA 3'UTR).